PUBLISHER: Allied Market Research | PRODUCT CODE: 1140204
PUBLISHER: Allied Market Research | PRODUCT CODE: 1140204
Nucleic acids are chemical substances and carry genetic information of the cell. The three types of nucleic acids are deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and artificial nucleic acid. Watson-Crick base pairing recognizes endogenous nucleic acids in a sequence-specific manner, mediating the shared mode of action of all nucleic acids. The nucleic acid-based therapies are widely used to treat various chronic diseases. Nucleic acid shows the significant therapeutic result in chronic diseases, such as cancer, tumor, diabetes, tuberculosis, and human immunodeficiency virus (HIV). For instance, in recent years, the global nucleic acid therapeutics has gained extensive attention. Moreover, the increasing chronic illnesses and the search for cure of chronic illnesses is an international concern, therefore nucleic acid therapeutics is observing increased attention.
The nucleic acid therapeutics shows long lasting effects through gene editing, gene inhibition, gene addition or gene replacement. Furthermore, the increase in chronic disease prevalence and patients seeking treatment of nucleic acid therapies help in the global nucleic acid therapeutics market growth. Nucleic acid therapeutics shows the long lasting and curative effects. The key drivers for the growth of the global nucleic acid therapeutics market are increasing chronic illness and immensely developing novel treatments of nucleic acids. The high cost of research and development and expensive treatments and technologies are some major elements restraining the market growth. High product demand and growing concentration of pharmaceutical companies on the development of treatment for nucleic acid therapeutics are additional factors that are driving the nucleic acid therapeutics market growth. The lack of treatment alternatives for cancer, muscular dystrophy, and human immunodeficiency virus (HIV) is the important reason for global nucleic acid therapeutics market expansion. The nucleic acid therapeutics market will revamp on approval of the developing therapies for amyloidosis by using antisense oligonucleotide to lower transthyretin (TTR) levels and dose escalation to investigate safety of ISTH0036 in glaucoma undergoing trabeculectomy patients. For instance, there are various therapies under pipeline, which are expected to serve the demand for nucleic acid therapies globally and contribute to the market growth.
The nucleic acid therapeutics is segmented on the basis of products, application, end user, and region. Based on the products, the market is bifurcated into anti-sense oligonucleotides (ASOS) and DNA aptamers, RNA interference [RNAi] and short interfering RNAs [siRNAs], and others. The others segment is further classified into antagomir and RNA sponge and locked nucleic acid. By application, the market is fragmented into monogenetic disorders and multi-genetic disorders. By end user, the market is segmented into hospitals & clinics and academic & research institutes.
Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Major key players that operate in the global nucleic acid therapeutics market are Agilent Technologies Inc., Alnylam Pharmaceuticals, Inc., Arbutus Biopharma Corporation, Arrowhead Pharmaceuticals, Benetic Biopharma, Inc., Caperna Inc. [Moderna], Copernicus Therapeutics, Genzyme (Sanofi), Ionis Pharmaceuticals, MERCK KGAA, Novartis AG, Phylogica, Protagonist Therapeutics, QIAGEN N.V., Sarepta Therapeutics, Silence Therapeutics plc., and Thermo Fisher Scientific Inc.
Key Benefits For Stakeholders
Key Market Segments
By Products
By Application
By End User
By Region